R1 RCM Inc. (NASDAQ:RCM) Receives Average Recommendation of “Moderate Buy” from Analysts

R1 RCM Inc. (NASDAQ:RCM) has been assigned an average recommendation of “Moderate Buy” from the thirteen research firms that are covering the firm, MarketBeat Ratings reports. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price target among brokerages that have issued ratings on the stock in the last year is $15.83.

Several brokerages have issued reports on RCM. Canaccord Genuity Group decreased their price objective on shares of R1 RCM from $16.00 to $15.00 and set a “buy” rating for the company in a research note on Thursday, May 9th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $19.00 price target on shares of R1 RCM in a research note on Friday. Guggenheim reduced their price target on shares of R1 RCM from $17.00 to $15.00 and set a “buy” rating for the company in a report on Friday, April 5th. Morgan Stanley reiterated an “overweight” rating and issued a $17.00 price target on shares of R1 RCM in a report on Tuesday, March 26th. Finally, KeyCorp restated a “sector weight” rating on shares of R1 RCM in a research note on Wednesday, April 10th.

R1 RCM Price Performance

Shares of NASDAQ:RCM opened at $12.56 on Monday. The company has a debt-to-equity ratio of 0.78, a quick ratio of 1.79 and a current ratio of 1.79. The firm has a market cap of $5.29 billion, a price-to-earnings ratio of -157.00 and a beta of 0.86. The firm has a fifty day moving average price of $12.43 and a 200 day moving average price of $11.86. R1 RCM has a fifty-two week low of $8.87 and a fifty-two week high of $18.70.

R1 RCM (NASDAQ:RCM) last issued its quarterly earnings data on Wednesday, May 8th. The healthcare provider reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.03). R1 RCM had a negative net margin of 1.39% and a negative return on equity of 1.16%. The firm had revenue of $603.90 million for the quarter, compared to analysts’ expectations of $612.88 million. The business’s revenue for the quarter was up 10.7% compared to the same quarter last year. As a group, sell-side analysts expect that R1 RCM will post -0.17 earnings per share for the current fiscal year.

Institutional Trading of R1 RCM

A number of hedge funds have recently modified their holdings of RCM. Advisors Asset Management Inc. purchased a new stake in R1 RCM in the 1st quarter worth approximately $27,000. ANTIPODES PARTNERS Ltd increased its stake in shares of R1 RCM by 429.5% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,623 shares of the healthcare provider’s stock worth $59,000 after purchasing an additional 4,561 shares in the last quarter. Salem Investment Counselors Inc. acquired a new position in shares of R1 RCM during the 4th quarter worth about $61,000. Van ECK Associates Corp increased its stake in R1 RCM by 20.5% during the 4th quarter. Van ECK Associates Corp now owns 6,141 shares of the healthcare provider’s stock worth $65,000 after buying an additional 1,044 shares in the last quarter. Finally, QRG Capital Management Inc. acquired a new position in R1 RCM in the 1st quarter valued at $132,000. Hedge funds and other institutional investors own 61.10% of the company’s stock.

About R1 RCM

R1 RCM Inc provides technology-driven solutions for the financial performance and patient experience of health systems, hospitals, and physician groups. It provides operating partnership/end-to-end solutions, which manages multiple aspects of the revenue cycle to realize financial leverage and revenue improvement for hospital and physician customers.